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Summary Residual retroperitoneal masses may remain after chemotherapy for metastatic non-seminomatous
testicular cancer, which harbour residual tumour or totally benign tissue (necrosis/fibrosis). These residual
masses may be effectively removed by a surgical resection. We evaluated current selection criteria and tried to
develop alternative criteria in a data set of 544 patients, who had retroperitoneal lymph node dissection of
residual masses. Six resection policies were identified from the literature. Two alternative policies were
developed with logistic regression analysis. Evaluation of the policies focused on the true-positive rate
(resection in case of tumour), and the false-positive rate (resection in case of necrosis). It appea'red that most
current policies use the size of the residual mass () 10 mm or >20 mm) as the predominant selection criterion.
This resulted in high true-positive rates (most >90%), but false-positive rates between 37% and 87%. The
alternative policies included five well-known predictors of necrosis in addition to residual mass size (primary
tumour histology, prechemotherapy levels of the three tumour markers alphafetoprotein (AFP), human
chorionic gonadotropin (HCG) and lactate dehydrogenase (LDH) and mass shrinkage during chemotherapy).
This strategy resulted in improved true- and false-positive rates, even when categories of the predictors were
simplified for practical application. We conclude that a simple statistical model, based on a limited number of
patient characteristics, provides better guidelines for patient selection than those currently used in clinical
practice.
Keywords: testicular cancer; residual mass; resection
Testicular cancer is the most common malignancy among
men in the age between 20 and 35 years. Fortunately, even
metastatic disease can currently be cured in the majority (60-
80%) of patients with non-seminomatous germ cell tumour,
since the introduction of cisplatin-based chemotherapy
(Peckham, 1988; Einhorn, 1990). After chemotherapy,
surgical resection is a generally accepted treatment to
remove residual retroperitoneal lymph node masses, since
these masses still harbour residual tumour in about half of
the patients. Alternatively, patients may be treated conserva-
tively, which includes follow-up with regular blood tests and
computerised tomography (CT) scans of the abdomen. A
uniform approach to the selection of patients for resection is
lacking (Toner et al., 1990; Fossa et al., 1992; Hendry et al.,
1993; Mulders et al., 1990; Steyerberg et al., 1993), and
percentages of surgically treated patients vary between 20%
(Mead et al., 1992; Tait et al., 1984) and 86% (Aass et al.,
1991). Therefore, several large cancer centres cooperated to
evaluate the selection criteria for resection.
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Resection of residual masses provides the histological
diagnosis, which may be purely benign with necrotic and/or
fibrotic remnants only (necrosis), or residual tumour (mature
teratoma or undifferentiated cancer). In the case of cancer,
two additional courses of chemotherapy are usually
recommended (Einhorn et al., 1981; Fox et al., 1993).
Although not proven, it may be assumed that this additional
therapy reduces the risk of relapse, in addition to the
resection itself. Resection of mature teratoma prevents
growth of the residual mass (Logothetis et al., 1982). In
contrast, resection of benign masses has no therapeutic
benefit. An ideal resection policy would, therefore, result in
surgical removal of all masses with residual tumour (mature
teratoma or cancer) and in a conservative treatment of all
masses with necrosis.
Current selection policies were evaluated in an interna-
tional data set from six study groups. A statistical model was
developed from this same data set, using several well-known
predictors of the histology of residual masses (Tait et al.,
1984; Donohue et al., 1987; Gelderman et al., 1988; Harding
et al., 1989; Toner et al., 1990; Mulders et al., 1990; Fossa et
al., 1992; Steyerberg et al., 1994; Gerl et al., 1995). Easy-to-
use alternative selection criteria were based on this analysis
and compared with the current policies.
Patients and methods
Patients
An international data set was collected, consisting of patients
with metastatic non-seminomatous testicular cancer, includ-
ing patients with pure seminoma and elevated levels of
prechemotherapy tumour markers, who underwent resection
of retroperitoneal residual masses after induction chemother-
apy with cisplatin-based chemotherapy (Steyerberg et al.,
1995). Excluded were patients with elevated tumour markers[alphafetoprotein (AFP) or human chorionic gonadotropin
(HCG)] at the time of surgery, patients with extragonadal
tumours, patients with pure seminoma and patients resected
after relapse of tumour following initial chemotherapy.
Individual patient data included basic patient identifica-
tion, histology at resection, and the following predictors:
presence of teratoma elements in the primary tumour,
prechemotherapy tumour marker levels [AFP, HCG, lactate
dehydrogenase (LDH)], and pre- and post-chemotherapy
mass size. Patients were included from Memorial Sloan-
Kettering Cancer Center (MSKCC, n = 121) (Toner et al.,
1990), Norwegian Radium Hospital (NRH, n = 127) (Fossa et
al., 1989a,b, 1992; Aass et al., 1991), Indiana University
Hospital (IUH, n =42) (Donohue et al., 1987), University
Hospital Groningen (UHG, n = 137) (Gelderman et al., 1986,
1988; Nijman et al., 1987; De Graaf et al., 1991), and four
other Dutch centres [University Hospitals of Nijmegen
(Mulders et al., 1990), Leiden, Amsterdam and Rotterdam
(Steyerberg et al., 1993): n =117]. Most European patients
were treated according to trial protocols of the EORTC and
MRC. In all centres, patients with residual abnormalities on
radiological studies were recommended to undergo resection.
Adherence to this recommendation was not evaluated in this
study. In addition, patients with initial bulky retroperitoneal
disease (diameter > 30 mm) were candidates for resection at
MSKCC (Toner et al., 1990), as well as UHG patients with
teratoma elements in their primary tumour from 1988
onwards (Gelderman et al., 1988). At NRH, resection was
performed routinely in all patients with retroperitoneal lymph
node enlargement at diagnosis (Aass et al., 1991). The 42
patients included in this analysis from Indiana (IUH) all had
a palpable prechemotherapy mass larger than 10 cm
(Donohue et al., 1987). This series thus represents a small
part only of the experience at IUH with resection of residual
masses. A total of 544 patients had all the required data
available for analysis, of whom 245 (45%) had resection of
necrosis only and 299 (55%) of residual tumour. Of these 299
patients, 68 had undifferentiated cancer (23%) and 231 had
mature teratoma (77%). Patients were treated between 1975
and 1993, with a minority (11%) treated before 1981, and
most between 1981 and 1985 (51%).
Methods
Current resection policies were evaluated in the international
data set. The probabilities of each residual histology
(necrosis, mature teratoma, undifferentiated cancer) were
calculated in masses that would be selected for resection and
in masses that would be treated conservatively according to
each policy. The policies were further evaluated as diagnostic
tests, using the histology at resection as the gold standard
diagnosis (Sox et al., 1988). The true positive rate (or
sensitivity) of a policy referred to the fraction of resected
patients among those with residual tumour. The false-positive
rate (or 1 minus specificity) referred to the fraction of
patients who would undergo resection among the patients
with necrosis. A perfect resection policy would have a true-
positive rate of 100% and a false-positive rate of 0%. Areas
under the receiver operating characteristic (ROC) curve were
estimated to facilitate comparison of the diagnostic quality of
the policies, assuming a logistic distribution of the data (Van
der Schouw et al., 1994). An area of 0.5 would arise if
patients with and without residual tumour were equally likely
to undergo resection. An area of 1.0 corresponds to a perfect
policy.
Alternative resection criteria were developed with logistic
regression analysis (SPSS/PC + v5.01 software; SPSS Inc,
Chicago, IL, USA, and SAS v6.04 software; SAS Institute
Inc, Cary, NC, USA). The probability of necrosis was
estimated for combinations of characteristics known before
resection (predictors). A previous analysis of the data set
showed that important predictors of necrosis were: the
absence of teratoma elements in the primary tumour,
prechemotherapy normal AFP, normal HCG, high LDH, a
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small post-chemotherapy mass size and a large shrinkage in
size during chemotherapy (Steyerberg et al., 1995). The latter
three predictors were modelled as continuous variables,
including transformations of post-chemotherapy size (square
root) and prechemotherapy LDH (logarithmic). This model
showed good results with extensive validation procedures,
including bootstrapping (Efron, 1983) and leave-one-study-
out evaluations. To facilitate application in clinical practice,
we simplified the analysis by categorising the prechemother-
apy LDH value (elevated vs normal according to the upper
limit of the normal range for each centre, post-chemotherapy
size (0-9 mm, 10-19 mm, 20-29 mm, 30-49 mm,
>50 mm) and shrinkage (reduction in maximum transversal
diameter <0%, 0-69.9%, >70%). Both for the original and
for the simplified model, we calculated areas under the ROC
curve (Harrell et al., 1982). True- and false-positive rates were
calculated with increasing cut-off values for the probability of
necrosis.
Comparison ofpolicies
The diagnostic quality of the policies could be compared with
the area under the ROC curve, with larger areas indicating
better policies. A limitation of the area under the ROC curve
is, however, that it does not consider the frequency of the
outcome (necrosis/tumour at resection), nor the relative
importance of misclassifications (Hilden, 1991). We, there-
fore, calculated a weighted classification error. The relative
importance (or weight) of missing residual tumour was set as
1, 2, 4, 8 and 16 times that of unnecesary action. The
weighted classification error was expressed as the number of
unnecessary resections of necrosis and was calculated as:
(number of unnecessary resections) +(weight x number of
missed resections of tumour).
McNemar's test for paired observations was used for
statistical comparisons between the policies (McNemar,
1947). Since the test assumes equal weights for false-positive
and false-negative misclassifications, fair statistical compar-
isons could only be made if one policy dominated, i.e. had
both a higher true- and a lower false-positive rate.
Verification bias
In this analysis, data are only available from patients where
the residual histology was verified by resection. These
patients were selected from the total population of patients
with normal tumour markers after chemotherapy according
to the centre-specific selection policies. These policies had
resulted in an average of 31% of the resections being
performed in masses with a size of 0-10 mm (Steyerberg et
al., 1995). This selection may have led to a bias, labelled
verification bias (Ransohoff and Feinstein, 1978; Begg and
Greenes, 1983). This bias would lead to overestimated true-
and false-positive rates, but to largely unbiased predicted
probabilities of necrosis. Correction for verification bias in
the international data set is difficult, since six different centres
participated. Fortunately, in one centre resection was
performed routinely (NRH, n = 127) (Aass et al., 1991),
such that virtual absence of verification bias might be
assumed here. This assumption was supported by the
observation that 43% of the NRH resections had been
performed in masses with a size of 0-10 mm. The policies
were, therefore, also evaluated separately in these 127
patients.
Results
Table I shows the current resection policies that were
evaluated. The histological distribution is shown in masses
that would be resected or treated conservatively according to
each policy. The first policy (resection of all masses > 10 mm)
has been widely applied in European centres (Mulders et al.,
1990; Jansen et al., 1991; Steyerberg et al., 1993). MassesEvaluation of resection policies
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> 10 mm are generally detected on CT scans, and this
practice thus corresponds to resection if residual masses are
detected on CT scans. It can be read from Table I that the
probability of necrosis was 38% in masses > 10 mm, in
contrast to 72% in masses < 10 mm. The second policy
(resection of masses >20 mm) has been used especially in
British centres (Tait et al., 1984; Mead et al., 1992; Hendry et
al., 1993). It would leave masses unresected with a low risk of
undifferentiated cancer (4%), but a considerable risk of
mature teratoma (30%). Policies 3 to 5 use one or more
patient characteristics in addition to residual mass size. If
resection is performed in all patients with a teratoma-positive
tumour (policy 3, Gelderman et al., 1988), the risk of leaving
tumour unresected reduces to 23% (15%+8%) compared
with 28% with policy 1. Policy 4 (Toner et al., 1990) leads to
similar risk of missing residual tumour compared with policy
1 (30% vs 28%). Policy 5 (Fossa et al., 1992) consists of
resection in all patients, except a small subgroup with
residual masses <20 mm and three favourable character-
istics (primary tumour teratoma-negative and prechemother-
apy AFP and HCG normal). This stringent practice does not
guarantee that no tumour is missed, but the risk is low
(6% +6% = 12%). Policy 6 (Donohue et al., 1987) consists of
conservative treatment of patients with a shrinkage over 70%
and a teratoma-negative primary tumour. Residual tumour
was found in 24% (17% + 7%) of these patients.
Alternative resection policies
Alternative resection policies were based on statistical
analysis of the international data set. The results of an
analysis with continuous predictors are presented in Table II
(Steyerberg et al., 1995). The probability of necrosis
corresponds to the sum score and can readily be calculated
for individual patients. Exact formulas to calculate the
probability of necrosis, mature teratoma and cancer are
presented in the Appendix.
A simplified model used categories instead of the
continuous predictors in the logistic regression original
model. It was anticipated that the performance of this
model would only be slightly worse than the original model,
while the application in clinical practice would be facilitated.
The categorised predictors as shown in Table III were
analysed simultaneously with residual mass size. All five
predictors had similar odds ratios (Table III: range 2.2-2.8).
Therefore, a 'simple score' was constructed by counting the
number of favourable characteristics.
Next, we used the two models (Table II and III) to derive
alternative resection strategies. These alternative strategies
use a cut-off value for the probability of necrosis. If the
predicted probability of necrosis is lower than the cut-off
value, resection is performed; if not, conservative treatment
will follow. The choice of the cut-off values was based on the
Table I Resection policies and the histology of residual masses
Total Necrosis Teratoma Cancer
RI n=544 n=245 n=231 n=68
Policy Resection if Ca 100% 45% 43% 13%
1 Residual masses>lOmm R 437 38% 47% 14%
C 107 72% 22% 6%
2 Residual masses>20mm R 313 29% 52% 19%
C 231 67% 30% 4%
3 Residual masses>, Omm or primary tumour R 482 41% 46% 13%
teratoma-positive C 62 77% 15% 8%
4 Residual masses> 1Omm or prechemotherapy R 480 42% 45% 14%
mass> 30mm C 64 70% 25% 5%
5 Residual masses>20mm or primary tumour R 508 42% 45% 13%
teratoma-positive or prechemotherapy C 36 89% 6% 6%
AFP/HCG elevated
6 Shrinkage in size<70% or primary R 456 39% 47% 14%
tumour teratoma-positive C 88 76% 17% 7%
All patients had normal tumour markers AFP and HCG after chemotherapy for metastatic non-seminomatous testicular cancer. R, patients
fulfilling resection criteria; C, patients fulfilling conservative treatment criteria.
Table II Prognostic score chart to estimate the probability of necrosis in residual retroperitoneal masses
Predictor Value Score
Primary tumour histology
Teratoma-negative +9 ......
Prechemotherapy markers
Normal AFP +9 ......
Normal HCG +8 ......
LDH/normal valuea 0.6 0.8 1.0 1.5 2.0 3.0 4.5
Score -5 -2 0 +4 + 7 +11 + 15 ......
Postchemotherapy mass size
Transversal diameter (mm)a 2b 5 10 20 30 50 100
Score -4 -6 -9 -13 -16 -20 -28 ......
Shrinkage
100 x (presize-postsize)/presizea -50 0 50 75 100
Score -7 0 +7 + 11 + 15 ......
Estimate individual probability of necrosis Sum score (add) ......
Sum score 10 15 20 25 30 35 40
Probability (%) 51 63 74 82 88 93 95
aContinuous variables; scores for intermediate values can be estimated with linear interpolation. bIf no mass is
detectable on the post-chemotherapy CT scan, a size of 2mm is assumed.observed probabilities with the current policies, which apply
cut-off values implicity. With 60% and 90% as extremes of
the probability of necrosis, two areas with a clear treatment
advice evolve. If the probability of necrosis is less than 60%,
resection should follow; if the probability exceeds 90%,
conservative treatment is advised. In between is a grey area,
where the decision to resect a residual mass depends on the
cut-off value applied (60%, 70%, 80% or 90%). Table IV
shows the probability of necrosis according to the simplified
logistic regression model. It can, for instance, be read that the
probability of necrosis is less than 60% in patients with a
residual mass >50 mm, in patients with a mass that
increased during chemotherapy, in patients with a low score
Table III Categorised predictors of necrosis in addition to residual
mass size
Characteristic OR 95% CI Score
Primary tumour teratoma-negative 2.7 1.8-4.2 0/1
Prechemotherapy AFP normal 2.4 1.5-3.9 0/1
Prechemotherapy HCG normal 2.2 1.4-3.4 0/1
Prechemotherapy LDH elevated 2.8 1.6-4.7 0/1
Shrinkage in mass)70% 2.2 1.3-3.9 0/1 +
Simple score 0-5
Odds ratios and 95% confidence intervals were calculated with
logistic regression analysis (n =544).
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(0 or 1 point), in patients with a mass of 20-29 mm and a
score of 2 points, and in patients with a mass of 30-49 mm
and a score of 3 points.
Evaluation ofpolicies
Table V shows the results of the evaluation of the current
policies, the alternative policies, and the extreme policy of
resection in all patients. The true-positive (TP) rate of the
current policies (except policy 2) exceeds 90%. This means that
over 90% of the patients with residual tumour would be
resected with these policies and that less than 10% of the
masses with tumour would be missed. The false-positive (FP)
rate varies between 37% and 87%, which means that a large
proportion of the patients with necrosis would undergo
resection unnecessarily. Policy 2 is remarkable, as both the
TP and FP rate are relatively low (74% and 37%). For the
alternative policies (7 and 8), it is clear that an increase ofthe
cut-off values for the probability ofnecrosis, leads to a larger
fraction of resected patients and to higher TP and FP rates.
Thus, the higher the required probability of necrosis for
conservative treatment, the lower the risk of missing tumour,
but the higher the risk ofunnecessary resection. The diagnostic
performance ofthe policies was further compared by the areas
under the ROC curve. The performance of policies 1, 2, 3, 4
and 6 was more or less similar (area 0.72, 0.74, 0.75, 0.69 and
0.75). Policy 5 had a better diagnostic ability (area 0.84),
similar to the alternative resection policies (7 and 8).
Table IV Probability (%) of necrosis is according to combinations of the simple score (Table
III) and residual mass size
Mass size Simple score
(mm) 0 1 2 3 4 5
0-9 .60 .60 >60 >70 >80 >90
10-19 .60 .60 >60 >70 >80 >90
20-29 .60 .60 .60 >60 >80 >90
30-49 .60 .60 .60 .60 >70 >80
>50 or -60 .60 .60 .60 .60 .60
increased mass
Table V Evaluation of resection policies in the 544 patients in the international data seta
Resected Classification error
Policy Selection criteria TP (%) FP (%) AUC (%) 1:1 2:1 4:1 8:1 16:1
1 Residual masses) 10mm 90 69 0.72 80 198 228 288 408 648
2 Residual masses>20mm 74 37 0.74 58 168 245 399 707 1323
3 Residual masses, 1Omm or primary 95 80 0.75 89 211 225 253 309 421
teratoma-positive
4 Residual masses,1Omm or 94 82 0.69 88 219 238 276 352 504
presize>30mm
5 Residual masses,20mm or primary 98.7 87 0.84 93 217 221 229 245 277
teratoma-positive or prechemotherapy
AFP or HCG elevated
6 Shrinkage<70% or primary 93 73 0.75 84 199 220 262 346 514
teratoma-positive
7 Table II: probability of necrosis; sum score 0.84
.60%; .13 85 38 64 136 180 268 444 796
.70%; .18 92 52 74 153 178 228 328 528
.80%; .23 96 73 86 190 201 223 267 355
.90%; .32 98.7 89 94 222 226 234 250 282
8 Table IV: probability of necrosis 0.82
.60% 79 30 57 138 202 330 586 1098
.70% 91 55 74 162 190 246 358 582
<80% 97 76 88 197 207 227 267 347
<90% 99.7 94 97 231 232 234 238 246
9 All patients 100 100 0.5 100 245 245 245 245 245
aFor eachpolicy, the table shows the true-positive (TP) rate, the false-positive (FP) rate, the area under the ROC curve (AUC), the percentage of
patients undergoing resection, and the classification error for varying weights (non-resection oftumour: resection ofnecrosis) ofmisclassification.Evaluation of resection policies
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For the alternative policies, cut-off values for the
probability of necrosis could be found where these policies
dominated over the current policies except policy 5. For
example, a cut-off value of 70% with policy 7 resulted in a
higher TP rate and a lower FP rate than policy 1 (P<0.001).
Similar comparisons were made between the alternative
policies and the current policies 2, 3, 4 and 6, which were
statistically significant (P<0.05). A cut-off value of 90%
leads to a similar performance as policy 5.
The misclassification error shown in Table V indicates that
the optimal cut-off value for the probability of necrosis in
policy 7 and 8 increases with the relative weight of missing
tumour. For example if two, four or eight unnecessary
resections are judged to be worth one case of tumour,
optimal cut-off values are 70%, 80% and 90% respectively. If
the ratio is increased to 16: 1 or higher, resection in all
patients (policy 9) is the optimal strategy, since this strategy
then has the lowest misclassification error among the policies.
Evaluation of the policies in the 127 largely unselected
patients confirms that verification bias is present in the true-
and false-positive rates (Table VI). As expected, the true- and
false-positive rates are lower than when evaluated on the
total data set for most policies. The areas under the ROC
curve are, however, similar to the initial estimates. Also, the
alternative policies 7 and 8 still dominate over the other
policies (higher TP and lower FP), except policy 5. Therefore,
verification bias does not influence our main findings
substantially.
Discussion
In this study we evaluated several selection policies for
surgery in patients who were successfully treated for
metastatic testicular cancer, as apparent from normal
tumour markers after chemotherapy. In 45% of these
patients, resection was unnecessary, since only totally benign
tissue was present. We found that currently recommended
policies would lead to resection in between 37% and 87% of
these patients. This variation is explained by the patient
characteristics considered for selection and the varying degree
of certainty that tumour is not missed. Alternative strategies
were developed that combine more characteristics than most
current policies and hence, have a better inherent diagnostic
ability (area under the ROC curve), Moreover, the degree of
certainty that tumour is not missed can be decided on by
weighing the relative importance of missing tumour against
unnecessary resection.
Currently used resection policies are mainly based on a
single characteristic, i.e. the size of the residual mass. The
policy to resect CT scan-detected masses of 10 mm or larger
is probably the most frequently used nowadays. Some
strategies include additional characteristics for the selection
of patients. Indeed, our previous analyses (Steyerberg et al.,
1994, 1995) indicate that other equipotent predictors include
the absence of teratoma elements in the primary tumour,
prechemotherapy tumour marker levels (AFP, HCG and
LDH), and mass shrinkage. Therefore, alternative criteria for
resection can be developed, so that small residual masses
(<10 mm) are resected if an unfavourable combination of
other characteristics is present and, on the other hand, larger
masses (e.g. 10- 19 mm or 20-29 mm) are treated conserva-
tively if other predictors are favourable. Indeed, unpublished
observations indicate that larger masses may show a further
reduction in size during follow-up.
Most of the current policies would lead to resection in the
majority of patients with residual tumour (true-positive rates
>90%). Resection of masses >,20 mm (policy 2), however,
resulted in a relatively low TP rate (74%), which meant that
26% of the masses with residual tumour would have been left
unresected. Although most of these masses would contain
mature teratoma without any undifferentiated cancer, this
low TP rate will currently be judged unacceptable by most
clinicians. This finding supports the shift from 20 mm as
selection criterion to 10 mm, where a 90% TP rate is
achieved. Further, a slightly less favourable performance
was observed with the policy to resect small residual masses if
the initial mass was relatively large (>30 mm) (Toner et al.,
1990). This is explained by the finding that a large shrinkage
is a predictor of necrosis (multivariate P-value =0.003),
rather than a predictor of tumour. The most stringent
currently applied selection policy (number 5) (Fossi et al.,
1992), resulted in a combination of the FP and TP rate
similar to the use of a high cut-off for the probability of
necrosis in the alternative policies (>90%). The similar
diagnostic ability is explained by the fact that the three
predictors used in this policy, in addition to mass size
(primary tumour teratoma-negative, prechemotherapy AFP
and HCG normal), were also used in the alternative
strategies. At lower cut-off values, these alternative strategies
Table VI Evaluation of resection policies in 127 largely unselected patients from the Norwegian Radium Hospital, Oslo, Norwaya
Resected Classification error
Policy Selection criteria TP (%) FP (%) AUC (%) 1:1 2:1 4:1 8:1 16:1
1 Residual masses> 1Omm 80 53 0.70 66 47 59 83 131 227
2 Residual masses>20mm 57 17 0.78 36 37 63 115 219 427
3 Residual masses>lOmm or primary 93 70 0.77 81 50 54 62 78 110
teratoma-positive
4 Residual masses, IOmm or 89 65 0.72 76 50 57 71 99 155
presize>30mm
5 Residual masses)20mm or primary 100 76 1.0 87 50 50 50 50 50
teratoma-positive or prechemotherapy
AFP or HCG elevated
6 Shrinkage<70% or primary 89 70 0.69 79 53 60 74 102 158
teratoma-positive
7 Table II: probability of necrosis; sum score 0.86
<60%; < 13 84 31 59 34 44 64 104 184
70%; 18 93 49 70 36 40 48 64 96
.80%; 23 98 70 84 47 48 50 54 62
90%; 32 100 91 95 60 60 60 60 60
8 Table IV: probability of necrosis 0.82
.60% 69 20 43 32 51 89 165 317
<70% 84 50 66 43 53 73 113 193
<80% 95 73 84 51 54 60 72 96
.90% 100 88 94 58 58 58 58 58
9 All patients 100 100 0.5 100 66 66 66 66 66
aFor each policy, the table shows the true-positive (TP) rate, the false-positive (FP) rate, the area under the ROC curve (AUC), the percentage of
patients undergoing resection, and the classification error for varying weights (non-resection oftumour: resection ofnecrosis) ofmisclassification.Evaluation of resection policies
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had better TP and FP rates than the other current policies.
For example, the policy to resect masses > 10 mm is
dominated by using Table II or Table IV with a cut-off
value of 70% for the predicted probability of necrosis.
Although the alternative selection strategies have better
diagnostic properties than most current policies, a dilemma
remains on the optimal cut-off value for the probability of
necrosis. This cut-off value is determined by the relative
importance of missing tumour and unnecessary resection.
The disadvantages of unnecessary resection include short-
term and long-term morbidity [especially retrograde or
anejaculation (Hendry et al., 1993; Nijman et al., 1987)],
mortality and financial costs. Resection of residual mature
teratoma or undifferentiated cancer prevents that the mass
may grow, and probably decreases the risk of relapse (Toner
et al., 1990; Logothetis et al., 1992). The latter benefits of
resection cannot readily be quantified but may be limited for
small residual masses (<20 mm), since resection may well be
feasible after follow-up of some months. If missing residual
tumour is judged at least 4 times as important as an
unnecessary resection, the optimal cut-off value is at least
80% for the probability of necrosis. If frequent follow-up is
difficult (Fossa et al., 1992), the risk of missing tumour may
be worth 8 or even 16 unnecessary resections, which leads to
more aggressive selection with a cut-off value of 90% or
resection in all patients as the preferred strategy.
Another consideration is the relative importance of
missing mature teratoma or undifferentiated cancer. If the
risks of mature teratoma in a small residual mass are
considered to be limited, decision-making on resection is
dominated by the probability of residual cancer. This
probability can be estimated with the formulas in the
Appendix (Steyerberg et al., 1995). If the probability of
cancer exceeds, for example, 5%, resection may be indicated,
although this implies a value judgment for resection ofcancer
relative to teratoma and necrosis.
Two limitations of this study have to be considered.
First, only operated patients were included and these
patients were selected with different criteria in the six
participating centres, Evaluation on a subsample with
virtually absent selection showed that this verification bias
had resulted in overestimated true- and false-positive rates.
The areas under the ROC curve were, however, largely
unaffected, resulting in the same ordering of the diagnostic
performance of the policies. Second, the alternative
resection policies have not yet been validated on a new,
independent data set. Although several less rigorous
validation procedures showed only minor overoptimism of
model performance, further conformation is required. We
are currently working on such a validation study, which
shows promising initial results.
We conclude that a policy that takes into account all
currently known predictors may result in improved selection
ofpatients for resection. This means that the balance between
the number of beneficial and unnecessary resections will be
favourably influenced by the clinical application of such a
policy.
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Appendix
The formulas to calculate the probability of each histology
are shown below. These formulas are implemented in a
simple spreadsheet program available from the authors (E-
mail: steyerberg@ckb.fgg.eur.nl).
Sumscore(necrosis):
-9.78 + 8.58 x 'teratoma-negative' + 8.70 x 'AFPnormal' +
7.61 x'HCGnormal'+ 9.69
In(LDH,t) -2.83 x Sqrt(postsize) +0.147 x shrinkage
Sumscore(cancer):
-24.18 + 3.95 x ln(LDHst) + 1.36 x Sqrt(postsize) +0.053 x shrinkage
The variables 'teratoma-negative', 'AFPnormal' and
'HCGnormal' are I if true, 0 if false, ln(LDH,t) is the
natural logarithm of LDH/upper limit of normal value;
postsize is expressed in mm and shrinkage is expressed as %.
The corresponding probabilities are calculated with the
formulas:
Probability (necrosis): 1/[1 +e- (Sumscore(Necrosis)/IO)]
Probability (cancer): [l-Probability(necrosis)] x
[1/(1 + e (Sumscore(Cancer)/IO))]
Probability(teratoma): 1- [Probability(necrosis) +
Probability(cancer)]